Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > ONLY 20 SHARES TRADED ON THE PINKS?

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Aug 21, 2020 6:17am

153 Views

Post# 31437129

RE:ONLY 20 SHARES TRADED ON THE PINKS?

JK, still moseying along. Waiting with bated breath for money, money, money to get the data, data, data (BoM2) on its way. Don may have run into a brick wall. He needs to knock it down and get the show on the road, now, eh !

G1945V

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price